Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0NVMET
ADC Name
T-VEd9
Synonyms
T-VEd9
   Click to Show/Hide
Organization
Zhejiang university.
Drug Status
Investigative
Drug-to-Antibody Ratio
8
Structure
Antibody Name
Trastuzumab
  Antibody Info 
Antigen Name
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
  Antigen Info 
Payload Name
Ed9
  Payload Info 
Therapeutic Target
DNA topoisomerase 1 (TOP1)
  Target Info 
Linker Name
Mc-Val-Ala
  Linker Info 
General Information of The Activity Data Related to This ADC
Discovered Using Cell Line-derived Xenograft Model
Click To Hide/Show 3 Activity Data Related to This Level
Standard Type Value Units Cell Line Disease Model
Tumor Growth Inhibition value (TGI) 
99.3
%
Undisclosed Undisclosed
Tumor Growth Inhibition value (TGI) 
100
%
Undisclosed Undisclosed
Tumor Growth Inhibition value (TGI) 
100
%
Undisclosed Undisclosed
Revealed Based on the Cell Line Data
Click To Hide/Show 4 Activity Data Related to This Level
Standard Type Value Units Cell Line Disease Model
Half Maximal Inhibitory Concentration (IC50) 
0.071
nM
CVCL_0418
Breast cancer
Half Maximal Inhibitory Concentration (IC50) 
0.091
nM
CVCL_1603
Gastric tubular adenocarcinoma
Half Maximal Inhibitory Concentration (IC50) 
0.674
nM
CVCL_0033
Breast cancer
Half Maximal Inhibitory Concentration (IC50) 
> 50
nM
CVCL_0062
Breast cancer
Full List of Activity Data of This Antibody-drug Conjugate
Discovered Using Cell Line-derived Xenograft Model
Click To Hide/Show 3 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI)
99.30%
In Vivo Model NCI-N87/MDA-MB-231 co-incubation model 2 mpk
Experiment 2 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI)
100%
In Vivo Model NCI-N87 CDX model 3 mpk
Experiment 3 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI)
100%
In Vivo Model NCI-N87 CDX model 1 mpk
Revealed Based on the Cell Line Data
Click To Hide/Show 4 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50)
0.071 nM
In Vitro Model Breast adenocarcinoma MDA-MB-453 cells CVCL_0418
Experiment 2 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50)
0.091 nM
In Vitro Model Gastric tubular adenocarcinoma NCI-N87 cells CVCL_1603
Experiment 3 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50)
0.674 nM
In Vitro Model Breast adenocarcinoma SK-BR-3 cells CVCL_0033
Experiment 4 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) > 50 nM
In Vitro Model Breast adenocarcinoma MDA-MB-231 cells CVCL_0062
References
Ref 1 Rational Identification of Novel Antibody-Drug Conjugate with High Bystander Killing Effect against Heterogeneous Tumors